The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis

OBJECTIVES: Recent trials have shown an overall survival (OS) benefit in 10-40% advanced cancer patients treated with programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. Here, we aimed to evaluate the relationship between PD-L1 expression and the therapeutic efficacy of P...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao-Jiang, Yuan, Shu-Qiang, Duan, Jin-Ling, Chen, Yong-Ming, Chen, Shi, Wang, Yun, Li, Yuan-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787798/
https://www.ncbi.nlm.nih.gov/pubmed/33488843
http://dx.doi.org/10.1155/2020/6717912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787798/
https://www.ncbi.nlm.nih.gov/pubmed/33488843
http://dx.doi.org/10.1155/2020/6717912

Ejemplares similares